NASDAQ
SGTX

Sigilon Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Sigilon Therapeutics Inc Stock Price

Vitals

Today's Low:
$22.47
Today's High:
$22.47
Open Price:
$22.47
52W Low:
$3.77
52W High:
$28
Prev. Close:
$22.47
Volume:
0

Company Statistics

Market Cap.:
$56.22 million
Book Value:
10.97
Revenue TTM:
$17.65 million
Operating Margin TTM:
-174.66%
Gross Profit TTM:
$-24687000
Profit Margin:
-171.29%
Return on Assets TTM:
-23.65%
Return on Equity TTM:
-76.31%

Company Profile

Sigilon Therapeutics Inc had its IPO on 2020-12-04 under the ticker symbol SGTX.

The company operates in the Healthcare sector and Biotechnology industry. Sigilon Therapeutics Inc has a staff strength of 62 employees.

Stock update

Shares of Sigilon Therapeutics Inc opened at $22.47 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $22.47 - $22.47, and closed at $22.47.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Sigilon Therapeutics Inc have increased by 0%.

Sigilon Therapeutics Inc's Key Ratios

Sigilon Therapeutics Inc has a market cap of $56.22 million, indicating a price to book ratio of 0.2521 and a price to sales ratio of 0.8715.

In the last 12-months Sigilon Therapeutics Inc’s revenue was $17.65 million with a gross profit of $-24687000 and an EBITDA of $-29579000. The EBITDA ratio measures Sigilon Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sigilon Therapeutics Inc’s operating margin was -174.66% while its return on assets stood at -23.65% with a return of equity of -76.31%.

In Q2, Sigilon Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 104.6%.

Sigilon Therapeutics Inc’s PE and PEG Ratio

Forward PE
2.7655
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-14.83 per share while it has a forward price to earnings multiple of 2.7655 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sigilon Therapeutics Inc’s profitability.

Sigilon Therapeutics Inc stock is trading at a EV to sales ratio of 1.4551 and a EV to EBITDA ratio of 0.7119. Its price to sales ratio in the trailing 12-months stood at 0.8715.

Sigilon Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$55.56 million
Total Liabilities
$25.25 million
Operating Cash Flow
$0
Capital Expenditure
$139000
Dividend Payout Ratio
0%

Sigilon Therapeutics Inc ended 2024 with $55.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $55.56 million while shareholder equity stood at $27.45 million.

Sigilon Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $25.25 million in other current liabilities, 3000.00 in common stock, $-271684000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.62 million and cash and short-term investments were $34.90 million. The company’s total short-term debt was $4,523,000 while long-term debt stood at $0.

Sigilon Therapeutics Inc’s total current assets stands at $44.87 million while long-term investments were $0 and short-term investments were $15.28 million. Its net receivables were $6.86 million compared to accounts payable of $1.11 million and inventory worth $250000.00.

In 2024, Sigilon Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $139000.

Comparatively, Sigilon Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$22.47
52-Week High
$28
52-Week Low
$3.77
Analyst Target Price
$58.67

Sigilon Therapeutics Inc stock is currently trading at $22.47 per share. It touched a 52-week high of $28 and a 52-week low of $28. Analysts tracking the stock have a 12-month average target price of $58.67.

Its 50-day moving average was $16.97 and 200-day moving average was $10.29 The short ratio stood at 0.11 indicating a short percent outstanding of 0%.

Around 869% of the company’s stock are held by insiders while 5432.9% are held by institutions.

Frequently Asked Questions About Sigilon Therapeutics Inc

The stock symbol (also called stock or share ticker) of Sigilon Therapeutics Inc is SGTX

The IPO of Sigilon Therapeutics Inc took place on 2020-12-04

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Shiva Mills Limited (SHIVAMILLS)
$75.84
-1.95
-2.51%
$79.01
-5.21
-6.19%
$11.1
1.12
+11.22%
$15.56
0.06
+0.4%
$45.31
-3.52
-7.21%
$34.12
-1.81
-5.04%
$0.05
0.01
+13.72%
$27.44
-0.56
-2%
BEML Limited (BEML)
$2311.95
-292.45
-11.23%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Address

100 Binney Street, Cambridge, MA, United States, 02142